Symptomtext
COVID 19 Treatment; COVID 19 Treatment; Vaccine brand other=Moderna,Vaccine dose number=4 / Vaccine brand=Pfizer / BioNTech, Vaccine dose number=5; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 69-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 21Oct2022 at 18:00 as dose 5 (booster), single (Lot number: GH3275) at the age of 68 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 14Jan2021 at 14:00 as dose 1, single (Lot number: 025J20-2A), in left arm, on 16Feb2021 at 16:00 as dose 2, single (Lot number: 041L20A), in left arm, on 24Oct2021 at 15:00 as dose 3 (booster), single (Lot number: 050c21A), in left arm and on 16May2022 at 13:00 as dose 4 (booster), single (Lot number: 001M21A), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Yes" (unspecified if ongoing), notes: Known allergies: Yes. The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 21Oct2022 at 18:00, outcome "unknown", described as "Vaccine brand other=Moderna,Vaccine dose number=4 / Vaccine brand=Pfizer / BioNTech, Vaccine dose number=5"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.